Tempus, a technology company focused on applying AI to precision medicine, has collaborated with Artera, a developer of multimodal AI for personalized cancer treatment, to expand access to prognostic tests for patients with prostate cancer. Tempus AI previously announced the launch of ArteraAI Prostate Test (mHSPC), a digital pathology–based prognostic test for patients with metastatic hormone-sensitive prostate cancer. Now clinically available, the test is certified under the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP). It will also be fully integrated into the Tempus platform, enabling clinicians to order it alongside Tempus’ portfolio of solid tumor testing tools. According to the companies, this is the first digital pathology algorithm available for clinical use through the Tempus platform.  

The partnership between the two companies was announced in February 2025. They are working to combine Tempus’ next-generation sequencing assays with Artera’s digital pathology-based AI tools to expand access to precision medicine solutions through the Tempus platform. 

The ArteraAI Prostate Test (mHSPC) generates a 5-year estimate of prostate cancer–specific mortality risk for patients receiving androgen-deprivation therapy and an androgen receptor pathway inhibitor. The estimate is based on a patient’s clinical data and histopathology images and is intended to help oncologists and urologists personalize treatment intensity.  

“As treatment options for metastatic hormone-sensitive prostate cancer have evolved, tools to accurately assess individual patient risk in the context of modern combination therapy have not fully evolved alongside them,” said Calvin Chao, MD, PhD, Vice President of Medical Science at Artera. “This clinically validated test is poised to help clinicians better tailor treatment intensity and duration to the individual patient.” 

“By establishing this new digital pathology workflow with the ArteraAI Prostate Test, we are giving clinicians a differentiated tool to better stratify risk and tailor therapy, helping ensure that patients with advanced prostate cancer receive a personalized, evidence-based treatment plan from the very start of their care journey,” stated Laura Elster, Chief Commercial Officer of Diagnostics at Tempus.

Artera’s multimodal AI–based prognostic and predictive cancer tests have been validated using data from multiple phase III randomized trials. The ArteraAI Prostate Test and its multimodal AI score—now available in several versions for different stages of disease—were validated in the phase III STAMPEDE trial. In that study, the score was significantly associated with prostate cancer–specific mortality, overall survival, failure-free survival, and progression-free survival.  

ArteraAI Prostate received de novo marketing authorization from the U.S. Food and Drug Administration (FDA) in August 2025, marking it as an FDA-regulated Software as a Medical Device. Additionally, in 2024, the ArteraAI Prostate Test was recommended in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for risk stratification in patients with localized prostate cancer.

ASCO AI in Oncology is published by Conexiant under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO^®). The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. For more information, see Policies.